An FDA Panel Voted 9-3 Against Capricor on Cardiomyopathy and Never Voted on the Endpoint That Passed
The ballot was the outcome. A drug’s strongest dataset sitting off the voting question is not a footnote, it is the whole result.
The Beats
Analysis
The Briefs
An FDA Panel Voted 9-3 Against Capricor on Cardiomyopathy and Never Voted on the Endpoint That Passed
Revtorpyk Got Its NCCN Category 1 Listing Two Months Before Celcuity Can Sell a Single Vial
NICE Backed Aficamten the Same Day the MHRA Authorised It, at a Price It Will Not Disclose
J&J Paid $785 Million for a Look at Something That Has Never Been in a Human
The Biosimilar Was Too Cheap to Sell. So the Price Went Up Fourfold.